Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.

Passenger-plane

More from Anticancer

More from Therapy Areas